ABT vs TECH · P/E 25, rev $44.33B vs P/E 65, rev $1.22B
Abbott Laboratories (ABT) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the ABT and TECH stock pages for the full models.
Not investment advice.